| [1] |
Borderi M, Calza L, Colangeli V, et al. Prevalence of sub-clinical vertebral fractures in HIV-infected patients[J]. New Microbiol,2014,37(1):25-32.
|
| [2] |
Gazzola L, Savoldi A, Bai F, et al. Assessment of radiological vertebral fractures in HIV-infected patients: clinical implications and predictive factors[J]. HIV Med,2015,16(9):563-571.
|
| [3] |
Borderi M, Calza L, Colangeli V, et al. Prevalence of sub-clinical vertebral fractures in HIV-infected patients[J]. New Microbiol,2014,37(1):25-32.
|
| [4] |
Ilha TASH, Comim FV, Copes RM, et al. HIV and vertebral fractures: a systematic review and metanalysis[J]. Sci Rep,2018,8(1):7838.
|
| [5] |
Buckens CF, de Jong PA, WP Mali, et al. Prevalent vertebral fractures on chest CT: higher risk for future hip fracture[J]. J Bone Miner Res,2014,29(2):392-398.
|
| [6] |
Kanis J. Diagnosis of osteoporosis and assessment of fracturerisk[J]. Lancet,2002,359(9231):1929-1936.
|
| [7] |
Latika GU, Able LA, Sukesh ED, et al. Prevalence and predictors of asymptomatic vertebral fractures in inflammatory myositis[J]. Int J Rheum Dis,2018,21(3):725-731.
|
| [8] |
Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK[J]. Osteoporos Int,2008,19:385-397.
|
| [9] |
Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK[J]. Osteoporos Int,2008,19(10):1395-1408.
|
| [10] |
Calmy A, Chevalley T, Delhumeau C, et al. Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal women[J]. Osteoporos Int,2013,24(6):1843-1852.
|
| [11] |
Biver E, Calmy A, Delhumeau C, et al. Microstructural alterations of trabecular and cortical bone in long-term HIV-infected elderly men on successful antiretroviral therapy[J]. AIDS,2014,23,28(16):2417-2427.
|
| [12] |
Yin MT, Lund E, Shah J, et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life[J]. AIDS,2014,28(3):345-353.
|
| [13] |
Yin MT, Shu A, Zhang CA, et al. Trabecular and cortical microarchitecture in postmenopausal HIV-infected women[J]. Calcif Tissue Int,2013,92(6):557-565.
|
| [14] |
Silva BC, Leslie WD, Resch H, et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image[J]. J Bone Miner Res,2014,29(3):518-530.
|
| [15] |
Silva BC, Broy SB, Boutroy S, et al. Fracture risk prediction by non-BMD DXA measures: the 2015 ISCD official positions Part 2: Trabecular Bone Score[J]. J Clin Densitom,2015,18(3):309-330.
|
| [16] |
Ulivieri FM, Silva BC, Sardanelli F, et al.Utility of the trabecular bone score (TBS) in secondary osteoporosis[J]. Endocrine,2014,47(2):435-448.
|
| [17] |
Lorenzo C, Pennica1 A, Argento JG, et al. Trabecular bone score (TBS) is associated with subclinical vertebral fractures in HIV infected patients[J]. Bone Miner Metab,2018,36:111-118.
|
| [18] |
Hoy J, Young B. Do people with HIV infection have a higher risk of fracture compared with those without HIV infection[J]. Curr Opin HIV/AIDS,2016,11(3):301-305.
|
| [19] |
Mccomsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers[J]. Clin Infect Dis,2010,51(8):937-946.
|
| [20] |
Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system[J]. J Clin Endocrinol Metab,2008,93(9):3499-3504.
|
| [21] |
王萍萍, 柯耀华, 张浩, 等. 绝经后妇女740例脆性骨折部位与骨密度关系的分析[J]. 中国科医学,2010,13(4):372-373.
|
| [22] |
Torti C, Mazziotti G, Soldini PA, et al. High prevalence of radiological vertebral fractures in HIV-infected males[J]. Endocrine,2012,41(3):512-7.
|
| [23] |
Borderi M, Calza L, Colangeli V, et al. Prevalence of sub-clinical vertebral fractures in HIV-infected patients[J]. New Microbiol,2014,37(1):25-32.
|
| [24] |
Moir S, Fauci AS. B cells in HIV infection and disease[J]. Nat Rev Immunol,2009,9(4):235-245.
|
| [25] |
Grigsby IFPL, Mansky LM, Gopalakrishnan R, et al. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss[J]. Biochem Biophys Res Commun,2010,394(1):48-53.
|
| [26] |
Borderi M, Gibellini D, Vescini F, et al. Metabolic bone disease in HIV infection[J]. AIDS,2009,23:1297-1310.
|
| [27] |
Calmy A, Staszewski S, Pozniak AL, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: A cross-sectional study[J]. J Infect Dis,2009,200(11):1746-1754.
|
| [28] |
Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial[J]. JAMA,2004,292(2):191-201．
|
| [29] |
Deeks SG. HIV infection, inflammation, immunosenecence, and aging[J]. Annu Rev Med,2011,62:141-155.
|
| [30] |
Wang L, Mondal D, La Russa VF, et al. Suppression of clonogenic potential of human bone marrow mesenchymal stem cells by HIV type 1: putative role of HIV type tat protein and inflammatory cytokines[J]. AIDS Res Hum Retroviruses,2002,18(13):917-931．
|
| [31] |
Albright P, Du P, Haas RE, et al. Evidence-based screening for low bone mineral density in HIV-infected men[J]. JANAC,2014,6(3):532-540.
|
| [32] |
Shahar E, Segal E, Rozen GS, et al. Vitamin D status in young HIV infected women of various ethnic origins: Incidence of vitamin D deficiency and possible impact on bone density[J]. Clinical Nutrition,2013,32(1):83-87.
|
| [33] |
Albright P, Du P, Haas RE, et al. Evidence-based screening for low bone mineral density in HIV-infected men[J]. J Assoc Nurses AIDS Care,2014,25(6):532-540.
|
| [34] |
Young B, Dao CN, Buchacz K, et al. Increased rates of bone fracture among HIV-infected persons in the HIV outpatient study (HOPS) compared with the US general population, 2000-2006[J]. Clin Infect Dis,2011,52(8):1061-1068.
|
| [35] |
Mayer KH, Amorosa V, Tebas P. Bone disease and HIV infection[J]. CID,2006,42(1):108-124.
|
| [36] |
Pinzone MR, Moreno S, Cacopardo B, et al. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis[J]. AIDS Rev,2014,16(4):213-222.
|
| [37] |
Johnell O, Amorosa V, Tebas P, et al. Associations between baseline risk factors and vertebral fracture risk in the multiple outcomes of raloxifene evaluation (MORE) study[J]. J Bone Miner Res,2004,19(5):764-772.
|
| [38] |
Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab[J]. Nat Rev Drug Discov,2012,11(5):4011-4119.
|